BiotechTube

SHR0302 quick release tablets + SHR0302 sustained-release tablets

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Diseases

Conditions

Autoimmune Diseases

Trial Timeline

Jan 16, 2024 → Feb 21, 2024

NCT ID
NCT06202612

About SHR0302 quick release tablets + SHR0302 sustained-release tablets

SHR0302 quick release tablets + SHR0302 sustained-release tablets is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Autoimmune Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT06202612. Target conditions include Autoimmune Diseases.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06202612Phase 1Completed

Competing Products

20 competing products in Autoimmune Diseases

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
77
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
33
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
52
Enteric-coated Mycophenolate SodiumNovartisPhase 3
77
Ianalumab + PlaceboNovartisPhase 3
77
VAY736NovartisPhase 2/3
65
remibrutinibNovartisPhase 1
33
RO7049665RochePhase 2
52
rituximab (Mabthera®) + PlaceboRochePhase 3
77
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)Swedish Orphan BiovitrumPhase 2
51
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
51
BMS-986165Bristol Myers SquibbPhase 1
32
NivolumabBristol Myers SquibbPhase 1
32
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
32
BMS-986165 + RosuvastatinBristol Myers SquibbPhase 1
32
SAR445088SanofiPhase 1
32
BIVV020SanofiPhase 1
32
rilzabrutinibSanofiPhase 2
51
rilzabrutinib + placeboSanofiPhase 3
76

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85